Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Drug Resistance

  Free Subscription


Articles published in J Virol

Retrieve available abstracts of 27 articles:
HTML format
Text format



Single Articles


    August 2017
  1. RAI DK, Diaz-San Segundo F, Campagnola G, Keith A, et al
    Attenuation of Foot-and-Mouth Disease Virus by Engineered Viral Polymerase Fidelity.
    J Virol. 2017;91.
    PubMed     Text format     Abstract available


    June 2017
  2. ABDELNABI R, Morais ATS, Leyssen P, Imbert I, et al
    Understanding the Mechanism of the Broad-Spectrum Antiviral Activity of Favipiravir (T-705): Key Role of the F1 Motif of the Viral Polymerase.
    J Virol. 2017;91.
    PubMed     Text format     Abstract available


    February 2017
  3. WANG W, Zhou J, Halambage UD, Jurado KA, et al
    Inhibition of HIV-1 Maturation via Small Molecule Targeting of the Amino-Terminal Domain in the Viral Capsid Protein.
    J Virol. 2017 Feb 15. pii: JVI.02155-16. doi: 10.1128/JVI.02155.
    PubMed     Text format     Abstract available


    October 2016
  4. XIONG S, Borrego P, Ding X, Zhu Y, et al
    A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activities against HIV-1, HIV-2 and Simian Immunodeficiency Virus.
    J Virol. 2016 Oct 19. pii: JVI.01839.
    PubMed     Text format     Abstract available


    September 2016
  5. WU Y, Gao F, Qi J, Bi Y, et al
    Resistance to mutant group-2 influenza neuraminidases of an oseltamivir-zanamivir hybrid inhibitor.
    J Virol. 2016 Sep 21. pii: JVI.01703.
    PubMed     Text format     Abstract available


    July 2016
  6. VAUSSELIN T, Seron K, Lavie M, Mesalam AA, et al
    Identification of a new benzimidazole derivative as an antiviral against hepatitis C virus.
    J Virol. 2016 Jul 13. pii: JVI.00404.
    PubMed     Text format     Abstract available


  7. MURGATROYD C, Pirrie L, Tran F, Smith TK, et al
    Structure-activity relationships of the Human Immunodeficiency Virus Type 1 maturation inhibitor PF-46396.
    J Virol. 2016 Jul 6. pii: JVI.01075.
    PubMed     Text format     Abstract available


    June 2016
  8. WEISSHAAR M, Cox R, Morehouse Z, Kyasa S, et al
    Identification and Characterization of Influenza Virus Entry Inhibitors Through Dual-Myxovirus High-Throughput Screening.
    J Virol. 2016 Jun 1. pii: JVI.00898.
    PubMed     Text format     Abstract available


  9. BETZ-STABLEIN BD, Topfer A, Littlejohn M, Yuen L, et al
    Single-molecule sequencing reveals complex genomic variation of hepatitis B virus during 15 years of chronic infection following liver transplantation.
    J Virol. 2016 Jun 1. pii: JVI.00243.
    PubMed     Text format     Abstract available


    May 2016
  10. KHATUN A, Shabir N, Seo BJ, Kim BS, et al
    The Attenuation Phenotype of a Ribavirin-Resistant Porcine Reproductive and Respiratory Syndrome Virus Is Maintained during Sequential Passages in Pigs.
    J Virol. 2016;90:4454-68.
    PubMed     Text format     Abstract available


    February 2016
  11. RUANGRUNG K, Suptawiwat O, Maneechotesuwan K, Boonarkart C, et al
    Neuraminidase Activity and The Resistance of 2009 Pandemic H1N1 Influenza Virus to Antiviral Activity in Bronchoalveolar Fluid.
    J Virol. 2016 Feb 24. pii: JVI.00013.
    PubMed     Text format     Abstract available


    December 2015
  12. LAI KK, Cheung NN, Yang F, Dai J, et al
    Identification of Novel Fusion Inhibitors of Influenza A Virus by Chemical Genetics.
    J Virol. 2015 Dec 16. pii: JVI.02326.
    PubMed     Text format     Abstract available


    November 2015
  13. AOKI M, Hayashi H, Yedidi RS, Martyr CD, et al
    The C5-substituted Tetrahydropyrano-tetrahydofuran-derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs Including Darunavir.
    J Virol. 2015 Nov 18. pii: JVI.01829.
    PubMed     Text format     Abstract available


  14. RAUGI DN, Smith RA, Gottlieb GS
    Four Amino Acid Changes in HIV-2 Protease Confer Class-Wide Sensitivity to Protease Inhibitors.
    J Virol. 2015 Nov 11. pii: JVI.01772.
    PubMed     Text format     Abstract available


    October 2015
  15. MARTINS AN, Waheed AA, Ablan SD, Huang W, et al
    ELUCIDATION OF THE MOLECULAR MECHANISM DRIVING DUPLICATION OF THE HIV-1 PTAP LATE DOMAIN.
    J Virol. 2015 Oct 28. pii: JVI.01640.
    PubMed     Text format     Abstract available


  16. SU Y, Chong H, Xiong S, Qiao Y, et al
    Genetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket.
    J Virol. 2015 Oct 7. pii: JVI.01741.
    PubMed     Text format     Abstract available


  17. BRENNAN G, Kitzman JO, Shendure J, Geballe AP, et al
    Experimental Evolution Identifies Vaccinia Virus Mutations in A24R and A35R That Antagonize the Protein Kinase R Pathway and Accompany Collapse of an Extragenic Gene Amplification.
    J Virol. 2015;89:9986-97.
    PubMed     Text format     Abstract available


    September 2015
  18. HASSOUNAH SA, Liu Y, Quashie PK, Oliveira M, et al
    Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in SIVmac239.
    J Virol. 2015 Sep 16. pii: JVI.02131.
    PubMed     Text format     Abstract available


  19. JIANG X, Feyertag F, Meehan C, McCormack G, et al
    Characterising the diverse mutational pathways associated with R5-tropic maraviroc resistance: HIV-1 that uses the drug-bound CCR5 coreceptor.
    J Virol. 2015 Sep 2. pii: JVI.01384.
    PubMed     Text format     Abstract available


    August 2015
  20. LIANG J, Mesplede T, Oliveira M, Anstett K, et al
    The combination of the R263K and T66I resistance substitutions in HIV-1 integrase is incompatible with high level viral replication and the development of high-level drug resistance.
    J Virol. 2015 Aug 26. pii: JVI.01881.
    PubMed     Text format     Abstract available


  21. GILL AJ, Kovacsics CE, Vance PJ, Collman RG, et al
    Induction of Heme Oxygenase-1 Deficiency and Associated Glutamate-Mediated Neurotoxicity is a Highly Conserved HIV Phenotype of Chronic Macrophage Infection that is Resistant to Antiretroviral Therapy.
    J Virol. 2015 Aug 12. pii: JVI.01495.
    PubMed     Text format     Abstract available


  22. ANSTETT K, Fusco R, Cutillas V, Mesplede T, et al
    Dolutegravir-selected HIV-1 containing the N155H/R263K resistance substitutions does not acquire additional compensatory mutations under drug pressure that lead to higher level resistance and increased replicative capacity.
    J Virol. 2015 Aug 5. pii: JVI.01725.
    PubMed     Text format     Abstract available


    July 2015
  23. BIGLEY TM, Reitsma JM, Terhune SS
    An Antagonistic Relationship between Human Cytomegalovirus pUL27 and pUL97 Activities during Infection.
    J Virol. 2015 Jul 29. pii: JVI.00986.
    PubMed     Text format     Abstract available


    June 2015
  24. ZHOU J, Price AJ, Halambage UD, James LC, et al
    HIV-1 Resistance to the Capsid-Targeting Inhibitor PF74 Results in Altered Dependence on Host Factors Required for Virus Nuclear Entry.
    J Virol. 2015 Jun 24. pii: JVI.00340.
    PubMed     Text format     Abstract available


  25. RESA-INFANTE P, Paterson D, Bonet J, Otte A, et al
    Targeting importin-alpha7 as a therapeutic approach against pandemic influenza viruses.
    J Virol. 2015 Jun 17. pii: JVI.00583.
    PubMed     Text format     Abstract available


  26. ZHOU S, Jones C, Mieczkowski P, Swanstrom R, et al
    Primer ID Validates Template Sampling Depth and Greatly Reduces the Error Rate of Next Generation Sequencing of HIV-1 Genomic RNA Populations.
    J Virol. 2015 Jun 3. pii: JVI.00522.
    PubMed     Text format     Abstract available


  27. FENEANT L, Potel J, Francois C, Sane F, et al
    New insights into the understanding of hepatitis C virus entry and cell-to-cell transmission by using the ionophore Monensin A.
    J Virol. 2015 Jun 3. pii: JVI.00192.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Drug Resistance is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: